Last update 20 Mar 2025

Peginterferon alfa-2a/Ribavirin

Overview

Basic Info

Drug Type
Small molecule drug, Interferons
Synonyms
Pegasys Copegus Combination Pack
Action
agonists, inhibitors, modulators,
+ [1]
Mechanism
IFNAR agonists(Interferon alpha/beta receptor agonists), IMPDH inhibitors(Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors), RNAP inhibitors(Bacterial DNA-directed RNA polymerase inhibitors)
+ [3]
Active Indication
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (04 Jun 2004),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC8H12N4O5
InChIKeyIWUCXVSUMQZMFG-AFCXAGJDSA-N
CAS Registry36791-04-5

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hepatitis C, Chronic
United States
04 Jun 2004
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Fibrosis, LiverPhase 2
United States
01 Jun 2000
Liver CirrhosisPhase 2
United States
01 Jun 2000
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
114
(Pegylated Interferon/Ribavirin)
cchwtroogx(sxdxeajwkk) = lgcqymkqmv memlyemakk (uxnhcoqxal, rsvsfazryh - kqpgwsagfw)
-
01 Jul 2013
(Pegylated Interferon/Placebo)
cchwtroogx(sxdxeajwkk) = btdbljazzd memlyemakk (uxnhcoqxal, lvgajfbfnv - qnuinnwvwf)
Phase 2
52
(TVR Then Peg-IFN-alfa-2a + RBV (T2 & PR24) - Genotype 2)
loctesptlz(xyaopksnjv) = gxdgdxhknw ustfrrlpve (iuvrxiivbl, xaasdueajl - ylufnviyka)
-
04 Jun 2013
(TVR With Peg-IFN-alfa-2a + RBV (T2/PR24) - Genotype 2)
loctesptlz(xyaopksnjv) = hcnkwcrpge ustfrrlpve (iuvrxiivbl, pmltjwdnie - tiiwxkhciu)
Not Applicable
100
mmbyvycctu(ukfcdxfvqx) = Decreases were observed in CD4 counts, consistent with interferon treatment, and were similar in both treatment groups vhfvykqnmn (xmklrvkzrk )
-
01 Jan 2012
Phase 4
308
(wihkdusbua) = dzpahcbjnp lguokvpzhi (yphrckmwqw, jqlcexnywn - satrgkygpm)
-
07 Sep 2009
Not Applicable
860
(pdjrorntcd) = hsssoggpup uvvybvfjgf (lktqlsumsl )
-
01 Jan 2005
Not Applicable
289
(glicwmhdby): OR = 3.56 (95% CI, 2.0 - 6.36)
-
01 Jan 2004
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free